Streetbeat News

Price Targets

RVPH

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:17 am

IONQ

Needham analyst Quinn Bolton maintains a Buy rating on IonQ (NYSE:IONQ) and raises the price target from $9 to $11.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:17 am

ESPR

HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $22 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:15 am

VRTX

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a $380 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:13 am

VICR

Needham analyst Quinn Bolton maintains a Buy rating on Vicor (NASDAQ:VICR) and raises the price target from $55 to $65.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:12 am

AGRX

HC Wainwright & Co. analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (NASDAQ:AGRX) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:11 am

TARS

HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $40 to $44.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:10 am

GTHX

HC Wainwright & Co. analyst Edward White reiterates a Buy rating on G1 Therapeutics (NASDAQ:GTHX) and maintains an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:09 am

GROY

HC Wainwright & Co. analyst Heiko Ihle reiterates a Buy rating on Gold Royalty (AMEX:GROY) and maintains an $8.75 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:08 am